The latest from Redeye about Scandinavian Life Science and Technology companies

Theme: Online Gambling

Get in the game and place your bets!

Find out more

Theme: Cybersecurity

Cyberattacks on the rise - Can we win the battle?

Find out more

Theme: Gaming

Super Investment Gaming Guide - In depths on the bits and pixels of the Gaming industry. GLHF

Find out more

Theme: Fight Cancer

There is a war on cancer and now, for the first time ever we see an opportunity for winning.

Find out more

Stillfront Group

Positive news from Goodgames Studios

Research Note 2018-01-09
SF
icon-company Stillfront Group

Positive news from Goodgames Studios

Research Note 2018-01-08 Kristoffer Lindström

Today Stillfront Group released user statistics for Q4’17. Compared to the previous quarter the number of DAU’s remained relatively flat, mostly due to reduced marketing effort on Siege Titan Wars. The engagement ratio increased significantly, which also likely have boosted the monetization ratio of the users. We trim our Q4 estimates slightly but make no changes to our valuation.

The most interesting takeaway from the user figures was a sharp rise in active players for Goodgames Studios compared to Q3, which implies a continued successful launch of Big Farm: Mobile Harvest.

Continue reading

PowerCell Sweden

Ny affär i Kina

Research Note 2018-01-09
PCELL
icon-company PowerCell Sweden

Ny affär i Kina

Research Note 2018-01-09 Henrik Alveskog

Powercell har fått en beställning från en kinesisk personbilstillverkare. Ordern avser ett antal S-2 stackar som skall användas som range extenders till elbilar.

Continue reading

Saniona

Interim study results presented in the Prader-Willi syndrome

Research Note 2018-01-08
SANION
icon-company Saniona

Interim study results presented in the Prader-Willi syndrome

Research Note 2018-01-08 Anders Hedlund

Saniona reported earlier today results from a phase IIa study in Prader-Willi syndrome. The study was subject to interim-analyses in October 2017 since some patients discontinued the study due to adverse effects.

Based on the results, a clinically meaningful weight loss, as well as a reduction in hyperphagia (food craving), was reported in the study.

Continue reading

Orexo

Zubsolv Rx data – December

Research Update 2018-01-08
ORX
icon-company Orexo

Zubsolv Rx data – December

Research Update 2018-01-08 Klas Palin

The lastest figures regarding market share and number of tablets and prescriptions sold of Orexo's drug Zubsolv has been released. Zubsolv is a treatment for people with opioid dependence.

Continue reading

Moberg Pharma

Rx pipeline for free

Research Update 2018-01-05
MOB
icon-company Moberg Pharma

Rx pipeline for free

Research Update 2018-01-05 Klas Palin

Following the Q3 2017 report, we have adjusted our forecasts slightly, which negatively impact our base case fair value.

At current share price levels (SEK 28), we however believe the market has taken a too pessimistic approach to the pipeline assets, while overrating the risk of additional financing of the MOB-015 trials.

Continue reading

Opus Group

New Jersey tillbaka på noll

Research Note 2018-01-08
OPUS
icon-company Opus Group

New Jersey tillbaka på noll

Research Note 2018-01-08 Henrik Alveskog

I fredags kom beskedet att myndigheten i New Jersey godkänner den protest som en av Opus konkurrenter lämnat in. Den preliminära tilldelningen till Opus är därmed inte längre aktuell. Gissningsvis kommer en ny upphandling inom det närmaste året, men vem som vinner den kan man bara spekulera i.

Continue reading

Promore Pharma

Uncertainty around PXL01 Phase III development in the U.S.

Research Update 2018-01-05
PROMO
icon-company Promore Pharma

Uncertainty around PXL01 Phase III development in the U.S.

Research Update 2018-01-05 Mathias Spinnars

Promore Pharma announced on January 2nd that Cellastra, their intended partner for the Phase III development of PXL01 in North America, did not meet their fundraising goal and hence did not opt in on the collaboration. Promore will now open up the door for other financing alternatives.

Continue reading

Events

19

Jan

Redeye Technology Report 2018

23

Jan

Redeye Early Bird - 23 jan

08

Feb

Investor After Work Göteborg - 8 feb

Announcements

Redeye hosts its first Investor Meeting in New York

Redeye bistod Acconeer i övertecknad IPO

Scout Gaming Groups IPO tecknad till 360 MSEK